# AccuPulse

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/accupulse

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Website: www.accupulse.com
- Total disclosed funding: $50M
- Latest round: Series A (Jun 17, 2024)
- Investors on record: 6

## About

Established in 2020 and based in Suzhou, China, AccuPulse Medical Technology Co. Ltd., trading as AccuPulse, operates as a medical equipment company that focuses on cardiac electrophysiology. The team comes from GE, Acutus Medical, and Johnson & Johnson, who have experience in R&D, registration, and commercialization of cardiac electrophysiological medical devices. The founder and CEO, Jie Yin graduated from Shanghai University of Finance and Economics and served as the Business Development and Investment Director of Wicresoft Medical Group. The company has R&D centers in Suzhou, China, and the United States. In December 2022, it was recognized by MedTech Outlook as one of the top 20 MedTech companies of the year. In March 2026, it raised over CNY 100 million in venture funding.

The company specializes in developing innovative technology platforms in cardiac electrophysiology. It has established a pipeline of nearly 10 products based on pulsed electric field ablation (PFA) and innovative 3D labeling. The products include PFA ablation devices and catheters, and 3D ECG(electrocardiogram) calibration systems. The 3D calibration system is mainly used to diagnose arrhythmia, find the source of arrhythmia, and guide ablation therapy.

The company generates revenue by providing PFA ablation devices and catheters, and 3D ECG (electrocardiogram) calibration systems.

## Funding rounds

- Series A, Jun 17, 2024, $6.9M — Lanwan Venture Capital
- Series A, Feb 7, 2024, $28M — Prosperity Investment, Shanghai Healthcare Capital
- Series A, May 20, 2022, $15M — YuanBio Venture, Qianhai Ark Capital, Shanghai Biomedical Fund

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Series A
- Shanghai Biomedical Fund — Series A
- Prosperity Investment — Series A
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series A
- Lanwan Venture Capital (https://capitalatlas.ai/funds/lanwan-venture-capital) — Series A